POUKALOV KONSTANTIN purchased 9.3% of their position (1.25M shares) of LANDOS BIOPHARMA, INC. on the open market
Open‑market purchase worth $20.00M — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 2/8/2021ACC: 0001209191-21-008587
Director10% Owner
Since Feb 2021
+1.25M
Net shares
Net buyer
$20.00M
Total acquired
1
Open market trades
1B · 0S
4
Total transactions
14.62M acquired · 13.37M disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
+13.37M
Price / share
—
Trade value
—
% of position
New position
2/8/2021
0.00→13.37M
Common Stock
Indirect
Shares
+1.25M
Price / share
$16.00
Trade value
$20M
% of position
9.3%
2/8/2021
13.37M→14.62M
Total
Net shares
+14.62M
Net value
$20M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 2/8/2021 | C · Conversion | +13.37M | — | — | New position | 0.00 | 13.37M |
| Common Stock Indirect | 2/8/2021 | P · Purchase | +1.25M | $16.00 | $20M | 9.3% | 13.37M | 14.62M |
| Total | +14.62M | $20M | ||||||
Derivative Transactions2
Series A Preferred Stock
Indirect
Converts to
Common Stock
5.88M shares
Shares
−5.88M
Strike price
Held after
0.00
Exercisable
—
2/8/2021
Series B Preferred Stock
Indirect
Converts to
Common Stock
7.49M shares
Shares
−7.49M
Strike price
Held after
0.00
Exercisable
—
2/8/2021
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series A Preferred Stock Indirect | Common Stock5.88M shares | 2/8/2021 | C · Conversion | −5.88M | — | 0.00 | |
| Series B Preferred Stock Indirect | Common Stock7.49M shares | 2/8/2021 | C · Conversion | −7.49M | — | 0.00 |